PMID- 26779631
OWN - NLM
STAT- MEDLINE
DCOM- 20170214
LR  - 20220409
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Print)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 7
DP  - 2016 Jul
TI  - Combination of platelet count and mean platelet volume (COP-MPV) predicts 
      postoperative prognosis in both resectable early and advanced stage esophageal 
      squamous cell cancer patients.
PG  - 9323-31
LID - 10.1007/s13277-015-4774-3 [doi]
AB  - The aim of this study is to search the most powerful prognostic factor from 
      routine blood test for esophageal squamous cell cancer (ESCC) patients. Multiple 
      laboratory tests were evaluated including those reflecting red blood cell 
      parameters (hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular 
      hemoglobin concentration (MCHC), and red blood cell distribution width (RDW)), 
      platelet morphological parameters (mean platelet volume (MPV) and platelet count 
      (PLT)), blood coagulation status (D-dimer), and tumor biomarker (CA19-9). Known 
      inflammatory indices (NLR and PLR) were also calculated. A total of 468 patients 
      who were diagnosed with ESCC between December 2005 and December 2008 were 
      retrospectively analyzed in this study. By utilizing univariate and multivariate 
      Cox proportional hazard analyses, we found that PLT and MPV were significantly 
      associated with overall survival (OS) and disease-free survival (DFS) of ESCC 
      patients, with optimal cutoff values of 212 and 10.6, respectively. Moreover, the 
      combination of the preoperative PLT and MPV (COP-MPV) was calculated as follows: 
      patients with both PLT (>/=212 x 10(9) L(-1)) and MPV (>/=10.6 fL) elevation were 
      assigned a score of 2, and patients with one or neither were assigned a score of 
      1 and 0. The COP-MPV was an independent prognostic factor for OS (hazard ratio 
      (HR) 0.378, 95 % confidence interval (CI) 0.241 to 0.593, P < 0.001, 0/2) and DFS 
      (HR 0.341, 95 % CI 0.218 to 0.534, P < 0.001, 0/2) in multivariate analyses. In 
      subgroup analyses for early (stages I and II) and locally (stage III) advanced 
      stage patients, COP-MPV was found significantly associated with OS and DFS in 
      each group (P = 0.025 and P = 0.018 for OS and P = 0.029 and P = 0.002 for DFS). 
      In conclusion, we considered that COP-MPV is a promising predictor for 
      postoperative survival in ESCC patients.
FAU - Zhang, Fan
AU  - Zhang F
AD  - National Cancer Center, Cancer Hospital and Institute, Chinese Academy of Medical 
      Sciences, Panjiayuannanli 17, Chaoyang District, Beijing, 100021, China.
FAU - Chen, Zhaoli
AU  - Chen Z
AD  - National Cancer Center, Cancer Hospital and Institute, Chinese Academy of Medical 
      Sciences, Panjiayuannanli 17, Chaoyang District, Beijing, 100021, China.
FAU - Wang, Pan
AU  - Wang P
AD  - National Cancer Center, Cancer Hospital and Institute, Chinese Academy of Medical 
      Sciences, Panjiayuannanli 17, Chaoyang District, Beijing, 100021, China.
FAU - Hu, Xueda
AU  - Hu X
AD  - National Cancer Center, Cancer Hospital and Institute, Chinese Academy of Medical 
      Sciences, Panjiayuannanli 17, Chaoyang District, Beijing, 100021, China.
FAU - Gao, Yibo
AU  - Gao Y
AD  - National Cancer Center, Cancer Hospital and Institute, Chinese Academy of Medical 
      Sciences, Panjiayuannanli 17, Chaoyang District, Beijing, 100021, China.
FAU - He, Jie
AU  - He J
AD  - National Cancer Center, Cancer Hospital and Institute, Chinese Academy of Medical 
      Sciences, Panjiayuannanli 17, Chaoyang District, Beijing, 100021, China. 
      prof.hejie@263.net.
LA  - eng
PT  - Journal Article
DEP - 20160116
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Platelets/*pathology
MH  - Carcinoma, Squamous Cell/*pathology/surgery
MH  - Esophageal Neoplasms/*pathology/surgery
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - *Mean Platelet Volume
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Postoperative Period
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC4990601
OTO - NOTNLM
OT  - Esophageal squamous cell cancer
OT  - Mean platelet volume
OT  - Platelet count
OT  - Prognosis
OT  - Scoring system
COIS- FUNDING: This study was supported by the National Natural Science Foundation of 
      China (81372219, 81301851, and U1302223) and Beijing Natural Science Foundation 
      (7141011). CONFLICTS OF INTEREST: None
EDAT- 2016/01/19 06:00
MHDA- 2017/02/15 06:00
PMCR- 2016/01/16
CRDT- 2016/01/19 06:00
PHST- 2015/11/04 00:00 [received]
PHST- 2015/12/29 00:00 [accepted]
PHST- 2016/01/19 06:00 [entrez]
PHST- 2016/01/19 06:00 [pubmed]
PHST- 2017/02/15 06:00 [medline]
PHST- 2016/01/16 00:00 [pmc-release]
AID - 10.1007/s13277-015-4774-3 [pii]
AID - 4774 [pii]
AID - 10.1007/s13277-015-4774-3 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 Jul;37(7):9323-31. doi: 10.1007/s13277-015-4774-3. Epub 2016 
      Jan 16.